Search
Now showing items 51-60 of 90
Assessing decision inputs in drug development between small, early stage companies and big pharma : is there is a difference?
(Massachusetts Institute of Technology, 2007)
The pipeline productivity challenge facing large, publicly traded pharmaceutical companies, collectively referred to as "Big Pharma," is well known. The unprecedented success Big Pharma achieved over the past few decades ...
Valuation of the use of biomarkers predictive of drug efficacy to enrich responders in oncology drug clinical development
(Massachusetts Institute of Technology, 2006)
I study several aspects of the value in performing oncology clinical trials using screening biomarkers to preferentially select and enroll responders. From trial reports and investigational reports on potential biomarkers, ...
Identification of clinical characteristics of large patient cohorts through analysis of free text physician notes
(Massachusetts Institute of Technology, 2005)
Background A number of important applications in medicine and biomedical research, including quality of care surveillance and identification of prospective study subjects, require identification of large cohorts of patients ...
Academia versus industry as a wellspring of new ideas in drug discovery : the case of oncology
(Massachusetts Institute of Technology, 2006)
The United States population is aging, and the need for novel approaches to treat and manage disease continues to grow. Among the diseases that will impact this population, cancer remains a therapeutic area with significant ...
Image guidance in cardiac electrophysiology
(Massachusetts Institute of Technology, 2006)
Cardiac arrhythmias are characterized by a disruption or abnormal conduction of electrical signals within the heart. Treatment of arrhythmias has dramatically evolved over the past half-century, and today, minimally-invasive ...
Innovative Alzheimer's disease clinical trial design in the coming age of biomarkers
(Massachusetts Institute of Technology, 2008)
Alzheimer's disease (AD) is a field with huge unmet need and only a few symptomatic treatments with limited efficacy have been made available to patients. With the testing of disease-modifying drugs in recent years, the ...
Regression analysis of oncology drug licensing deal values
(Massachusetts Institute of Technology, 2006)
This work is an attempt to explain wide variations in drug licensing deal value by using regression modeling to describe and predict the relationship between oncology drug deal characteristics and their licensing deal ...
Drug-encapsulating EGF-sensitive liposomes for EGF-overexpressing cancer therapies
(Massachusetts Institute of Technology, 2009)
'Smart' targeted drug carriers have long been sought after in the treatment of epidermal growth factor (EGF)-overexpressing cancers due to the potential advantages, relative to current clinical therapies (generally limited ...
Lung tissue engineering : in vitro synthesis of lung tissue from neonatal and fetal rat lung cells cultured in a three-dimensional collagen matrix
(Massachusetts Institute of Technology, 2004)
The focus of this study was to investigate the histology of tissue formed when fetal (16-20 days gestation) and neonatal (2 days old) rat lung cells were grown in a collagen-glycosaminoglycan scaffold. This project employed ...
A wireless wide area network PDA application for on-call ambulatory care physicians
(Massachusetts Institute of Technology, 2004)
Current implementations of patient information review on Personal Digital Assistants (PDAs) are gaining traction in the in-patient hospital setting. There are tremendous patient safety and satisfaction, workflow improvement ...